NCT03089827

Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease

Enrolling by Invitation
Not specifiedAges 55+Observational
Wake Forest University Health Sciences
~800 participants
Updated 2025-12-22 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Amyloid deposition
Measured over 2 years
Alzheimer Disease
Mild Cognitive Impairment
1 sites across 1 states
North Carolina1
  • Suzanne Craft, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Enrolled in a study with the Alzheimer's Disease Research Center.
  • Amyloid deposition2 years

    Studying the initial amyloid deposition in participants as well as their rate of amyloid accumulation over time will help establish whether there is an early therapeutic window for intervention in high risk patients.